Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2023-03-13 Share Issue/Capital Cha…
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, grant date, and board resolution details. This type of disclosure regarding capital structure changes and employee compensation via stock options is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for director/insider trading) or SHA (which is for new share issues/capital changes).
2023-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kolon TissueGene, Inc. It contains the agenda for the upcoming Annual General Meeting (AGM), including items for approval such as financial statements, election of directors, and auditor appointments. It also includes detailed proxy information, such as the 'Proxy Solicitation Form' (의결권행사 신청서) and background information for shareholders to make informed voting decisions. This document is a classic Proxy Statement/Information Statement used to solicit votes for an AGM.
2023-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Kolon TissueGene) announcing a significant change (over 30%) in financial performance (revenue/profit/loss). This type of disclosure is a standard regulatory requirement in the Korean market (KRX) for listed companies to report material financial changes before the final audit is completed. It fits the 'Earnings Release' (ER) category as it provides key financial highlights and the reasons for the variance, rather than being a full annual report or a simple report publication announcement. FY 2022
2023-02-10 Korean
기타경영사항(자율공시)(제24기 정기주주총회 권리주주 확정을 위한 증권예탁증권(KDR) 기준일 설정 공고)
AGM Information Classification · 95% confidence The document is a regulatory announcement from Kolon TissueGene regarding the setting of a record date for the 24th Annual General Meeting (AGM) to determine voting rights for Korean Depositary Receipt (KDR) holders. It is a formal notice of a corporate action related to shareholder meetings and voting rights, which does not fit into specific categories like AGM-R (presentation materials) or DVA (results of a vote). As it is a general regulatory announcement regarding corporate governance procedures, it falls under the RNS category.
2022-12-13 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Kolon TissueGene, Inc. covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial information, business operations, management discussion, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
기타시장안내(위원회 심의결과 및 상장유지 결정 안내)
Delisting Announcement Classification · 100% confidence The document is a short regulatory announcement from the Korea Exchange regarding Kolon TissueGene. It details the outcome of a committee review (Corporate Review Committee and KOSDAQ Market Committee) which resulted in the decision to maintain the company's listing and resume trading. Since this is a regulatory announcement regarding market status and does not fit into specific categories like delisting or financial reporting, it is classified as a general regulatory filing.
2022-10-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.